Dissociated Glucocorticoids with Anti-Inflammatory Potential Repress Interleukin-6 Gene Expression by a Nuclear Factor-κB-Dependent Mechanism
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Synthetic glucocorticoids (GCs) remain among the most effective agents for the management of chronic inflammatory diseases. However, major side effects severely limit their therapeutic use. Physiologic and therapeutic activities of GCs are mediated by a nuclear receptor belonging to a superfamily of ligand-inducible transcription factors that, in addition to directly regulating their cognate gene programs, can also mutually interfere with other signaling pathways. We recently identified selective ligands of the glucocorticoid receptor that dissociate transactivation from activator protein 1 transrepression, and most importantly retain in vivo anti-inflammatory activity. To further document the mechanisms of action sustaining the observed in vivo activity, we report here on the interference of dissociated GCs with nuclear factor kB (NF-kB)-driven gene activation. We show that dissociated GCs repress tumor necrosis factor-induced interleukin-6 gene expression by an NFkB-dependent mechanism, without changing the expression level of inhibitor kB. The DNA-binding activity of induced NF-kB also remained unchanged after stimulation of cells with the various compounds. Evidence for a direct nuclear mechanism of action was obtained by analysis of cell lines constitutively expressing a fusion protein between the DNA-binding domain of the yeast Gal4 protein and the transactivating p65 subunit of NF-kB, which was able to efficiently repress a Gal4-dependent luciferase reporter gene upon addition of the dissociated compounds. We therefore conclude that, in addition to dissociating transactivation from activator protein 1 transrepression, dissociated GCs mediate inhibition of NF-kB signaling by a mechanism that is independent of inhibitor kB induction. Physiologic and therapeutic activities of glucocorticoids (GCs) are mediated by a nuclear receptor (NR), which is a member of the family of ligand-inducible transcriptional regulators for steroids and thyroid hormones, as well as for retinoids and vitamin D3 (for overview, see Nuclear Receptors Nomenclature Committee, 1999). In addition to directly regulating gene expression via binding as homodimers to cognate response elements in target gene promoters, the glucocorticoid receptor (GR) can also mutually interfere with other signaling pathways such as those utilizing AP-1 or nuclear factor kB (NF-kB). The latter mechanism, referred to as transcriptional crosstalk, is generally not restricted to these two transcription factor families, but can also involve factors such as STAT5, C/EBP, or Oct-2A (Göttlicher et al., 1998; Resche-Rigon and Gronemeyer, 1998). NF-kB is an inducible transcription factor complex that regulates the expression of various genes involved in inflammatory and immune responses. It is activated upon exposure of cells to proinflammatory cytokines [tumor necrosis factor (TNF), interleukin (IL)-1], oxidants (H2O2, ozone, superoxide anions), bacterial compounds (lipopolysaccharide), viral products (dsRNA, HTLV-1 Tax protein), protein kinase C activators (phorbol esters, platelet-activating factor), and UVor g-irradiation. In most cells, NF-kB is composed of a heterodimer of RelA (p65) and NF-kB1 (p50), where the RelA protein is responsible for the transactivation potential. In the nonactivated state, NF-kB is sequestered in the cytoplasm by 1 This work was supported by the Interuniversitaire Attractiepolen. G.H. is a Research Director with the Fonds voor Wetenschappelijk Onderzoek— Vlaanderen. K.D. holds a fellowship from the Vlaams Instituut voor de Bevordering van het Wetenschappelijk-Technologisch Onderzoek in de Industrie. ABBREVIATIONS: GC, glucocorticoid; DBD, DNA-binding domain; DEX, dexamethasone; HTC, hepatoma cell; I-kB, inhibitor kB; NF-kB, nuclear factor kB; TNF, tumor necrosis factor; IL, interleukin; TRE, tumor-promoting agent-responsive element; GR, glucocorticoid receptor; NR, nuclear receptor; DMEM, Dulbecco’s modified Eagle’s medium; FCS, fetal calf serum; TBS, Tris-buffered saline; ELISA, enzyme-linked immunosorbant assay; ERK, extracellular signal receptor-activated kinase; MAPK, mitogen-activated protein kinase; AP-1, activator protein 1; GRE, glucocorticoid-responsive element; MMTV, mouse mammary tumor virus; ERK, extracellular signal-regulated kinase. 0026-895X/99/040797-10$3.00/0 Copyright © The American Society for Pharmacology and Experimental Therapeutics All rights of reproduction in any form reserved. MOLECULAR PHARMACOLOGY, 56:797–806 (1999). 797 at A PE T Jornals on Sptem er 0, 2017 m oharm .aspeurnals.org D ow nladed from interaction with the inhibitor kB (I-kB) protein I-kB-a. During activation, the I-kB-a protein becomes phosphorylated and degraded, allowing NF-kB to translocate to the nucleus, where it binds to specific DNA elements and subsequently activates transcription (Mercurio and Manning, 1999). In this respect, NF-kB may be a promising target for antiinflammatory and immunosuppressive therapies (Baeuerle and Baichwal, 1997). Inhibition of NF-kB activity by GC has been well documented, although stimulatory effects have also been observed (for a review see Dumont et al., 1998; McKay and Cidlowski, 1998). This inhibition has been proposed to result from direct interaction between GR and the p65 subunit of NF-kB (Ray and Prefontaine, 1994; Liden et al., 1997; Wissink et al., 1997). Alternatively, induction of I-kB-a synthesis by GC, and the subsequent sequestration of NF-kB, was suggested to be a nonexclusive mechanism (Auphan et al., 1995; Scheinman et al., 1995). However, we and others have recently shown that in many cell types I-kB-a protein levels do not increase, or even decrease after dexamethasone (DEX) treatment, which suggests that the observed effect of GC may be tissueor cell-specific (De Bosscher et al., 1997; for review, see Dumont et al., 1998 and references included). Furthermore, it should be noted that elevated I-kB-a levels do not necessarily lead to dissociation of NF-kB from its binding site on DNA, nor repress the activity of NF-kB (Heck et al., 1997). Accordingly, GR mutants, in which point mutations in the GR DNA-binding domain (DBD) impaired DBD dimerization and DNA binding, and subsequently abolished GR transactivation, are unable to trigger synthesis of I-kB-a but retain their full ability to inhibit NF-kB activation (Heck et al., 1997; Liden et al.,
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A., & Karin, M. (1995) · Science · doi:10.1126/science.270.5234.286 · Cited by 2,390 · cited 2×
“…of NF-kB activity exerted by the dissociated GC is mediated via the GR. DEX has been shown to impair the TNF- or IL-1-induced DNA binding of NF-kB in a glioblastoma cell line, and in HeLa and T cells stably overexpressing the GR (Auphan et al., 1995; Scheinman et al., 1995; Dumont et al., 1998).”
Zhong, H., Voll, R. E., & Ghosh, S. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80066-0 · Cited by 1,210
A unified nomenclature system for the nuclear receptor superfamily
(1999) · Cell · doi:10.1016/s0092-8674(00)80726-6 · Cited by 1,208
The Pathophysiologic Roles of Interleukin-6 in Human Disease
Papanicolaou, D. A., Wilder, R. L., Manolagas, S. C., & Chrousos, G. P. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-2-199801150-00009 · Cited by 1,146 · cited 1×
“Overexpression of IL-6 has been implicated in the pathology of a number of diseases (Papanicolaou et al., 1998).”
BackgroundDNA binding of the glucocorticoid receptor is not essential for survival
Reichardt, H. M., Kaestner, K. H., Tuckermann, J., Kretz, O., Wessely, O., Bock, R., Gass, P., Schmid, W., Herrlich, P., Angel, P., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81183-6 · Cited by 1,068 · cited 1×
“In parallel, the genetic analysis of GR mutant mice defective in GR dimerization and GR binding to DNA (Reichardt et al., 1998), is in progress to assess the exact contribution of GR-mediated transactivation and transrepression in vivo.”
BackgroundAntagonism of glucocorticoid receptor transcriptional activation by the c-Jun N-terminal kinase
Rogatsky, I., Logan, S. K., & Garabedian, M. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.5.2050 · Cited by 297
CREB-binding protein in androgen receptor-mediated signaling
Aarnisalo, P., Palvimo, J. J., & Jänne, O. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.5.2122 · Cited by 255
Cited by
Newton, R., & Holden, N. S. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.038794 · Cited by 328
Kaileh, M., Vanden Berghe, W., Heyerick, A., Horion, J., Piette, J., Libert, C., De Keukeleire, D., Essawi, T., & Haegeman, G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m606728200 · Cited by 301
Self-citationBeck, I. M. E., Vanden Berghe, W., Vermeulen, L., Yamamoto, K. R., Haegeman, G., & De Bosscher, K. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0013 · Cited by 298
Self-citationMinireview: Latest Perspectives on Antiinflammatory Actions of Glucocorticoids
De Bosscher, K., & Haegeman, G. (2009) · Molecular Endocrinology · doi:10.1210/me.2008-0283 · Cited by 284
Self-citationAnti-inflammatory functions of glucocorticoid-induced genes
Clark, A. R. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.04.013 · Cited by 274
Metadata
- Authors
- Vanden Berghe, W., Francesconi, E., De Bosscher, K., Resche-Rigon, M., & Haegeman, G.
- Venue
- Molecular Pharmacology
- Publisher
- Elsevier BV
- Published
- 1999-10
- Volume
- 56
- Issue
- 4
- Pages
- 797-806
- ISSN
- 0026-895X (ISSN-L)
- OpenAlex
- W4405992937
- Cited by
- 47
- References
- 7
- FWCI
- 0.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dissociated Glucocorticoids with Anti-Inflammatory Potential Repress Interleukin-6 Gene Expression by a Nuclear Factor-κB-Dependent Mechanism. https://app.cochat.ai/papers/10.1016/s0026-895x(24)12543-6
- The paper
- Vanden Berghe, W., Francesconi, E., De Bosscher, K., Resche-Rigon, M., & Haegeman, G. (1999). Dissociated Glucocorticoids with Anti-Inflammatory Potential Repress Interleukin-6 Gene Expression by a Nuclear Factor-κB-Dependent Mechanism. Molecular Pharmacology. https://doi.org/10.1016/s0026-895x(24)12543-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.